SLC5A2 and diabetes mellitus: SGLT-2 inhibitors are widely prescribed antidiabetic drugs that block the renal reabsorption of glucose resulting in urinary glucose loss that promotes euglycemia in people with diabetes (43), and have been recently shown to have remarkable cardioprotective effects in patients independently from lowering blood glucose (32, 44).